ADAP / Adaptimmune: Underappreciated Biotech With BLA Filing Q4 Of 2022

The latest trading day saw Adaptimmune Therapeutics PLC (ADAP) settling at $0.55, representing a -1.79% change from its previous close. more_horizontal

Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - October 25, 2023) - Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leade more_horizontal

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - August 3, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in ce more_horizontal

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include OpGen (OPGN), Adaptimmune Therapeutics (ADAP), more_horizontal

GSK announces the FDA's extension of the review period of its new drug application for momelotinib to treat myelofibrosis by three months. A decision more_horizontal

The heavy selling pressure might have exhausted for Adaptimmune Therapeutics PLC (ADAP) as it is technically in oversold territory now. In addition to more_horizontal

Adaptimmune Therapeutics plc (NASDAQ:ADAP ) Q1 2023 Earnings Conference Call May 12, 2023 8:00 AM ET Company Participants Juli Miller - Head-Investor more_horizontal

Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - April 28, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader more_horizontal